Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00445510 |
This will be a single centre, randomised, double-blind, placebo-controlled, 2-period crossover study to investigate the effect of treatment with repeat inhaled doses of GSK256066 on bronchial hyper-reactivity to adenosine monophosphate.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: GSK256066 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Crossover Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | A Double Blind, Placebo Controlled, Repeat Dose Study to Determine the Effect of GSK256066 87.5 Mcg to Protect Against AMP Challenge in the Lung in Mild Steroid-Naive Asthmatics. |
Estimated Enrollment: | 24 |
Study Start Date: | June 2006 |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion: (All must Apply)
Exclusion:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | IPA106620 |
Study First Received: | March 7, 2007 |
Last Updated: | January 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00445510 History of Changes |
Health Authority: | New Zealand: Health and Disability Ethics Committees |
GSK256066, allergen, AMP, |
challenge, repeat dose, mild asthmatics |
Asthma |